The Lancet’s latest review of mRNA vaccines, by Blakney and colleagues, presents itself as an authoritative synthesis of the evidence.
Titled “Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective,” it promises to examine the mRNA platform from mechanistic, preclinical, clinical, and public health perspectives.
Instead, it delivers a remarkably confident account that gives little attention to many of the scientific and regulatory questions that have shaped debate over the past five years.
What makes the review effective as messaging is not that it ignores controversy, but that it appears to engage with it.
It names difficult issues — residual DNA, biodistribution, frameshifting, and IgG4 class switching — only to swiftly minimise them with reassuring language.
The effect is to create the appearance of critical scrutiny while reassuring readers that these concerns are either resolved or insignificant.
The review describes mRNA vaccines as a “transformative advance” characterised by “rapid clearance,” “lack of genomic integration,” and a “favourable safety profile.” It concludes that the accumulated evidence “affirms” the platform as safe, effective, and adaptable.
Ironically, the review sits behind a paywall. Most journalists will never read it, many doctors will see only the abstract, and policymakers are likely to rely on its conclusions without examining the evidence in detail.
Having spent more than five years examining regulatory decisions, FOI documents, advisory committee meetings, and independent laboratory findings on mRNA vaccines, I expected the review to grapple with the questions that repeatedly emerged during those investigations. But it didn’t.
The authors note that after injection, mRNA lipid nanoparticles “remain largely localised to the injection site” with “limited distribution” to secondary organs. The review also notes that vaccine mRNA has been detected in human plasma for up to 14 days in some recipients, and that mRNA and spike antigen have been found in draining lymph nodes for up to 60 days.
But these findings are quickly reframed as evidence of “rapid clearance” and “short-lived antigen expression” — a conclusion presented with far greater confidence than the underlying evidence appears to warrant.
Only last year, members of the CDC’s vaccine advisory committee questioned the manufacturers after discovering that biodistribution studies had never been conducted using the commercial vaccine administered to millions of people.
When asked directly whether those studies had been performed, company representatives struggled to answer, exposing important gaps in the evidence base. Yet those gaps receive little attention in the review.
Residual DNA is treated similarly.
